Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | PHASE2 | RECRUITING | 720 | — | — | Mar 23, 2018 | Jan 31, 2027 | Mar 27, 2026 | 10 | Canada |
over the total number of patients in a given cohort.
| Arm | Type | Description |
|---|---|---|
| Group 1 - Arm CLOSED, no patients recruited | EXPERIMENTAL | VEGFR1, VEGFR2, VEGFR3 |
| Group 2 - Arm CLOSED, no patients recruited | EXPERIMENTAL | BCR-ABL, SRC |
| Group 3 - Arm CLOSED | EXPERIMENTAL | ALK, ROS1, MET |
| Group 4 - Arm CLOSED, no patients recruited | EXPERIMENTAL | KIT, PDGFRA, PDGFRB, ABL1 |
| Group 5 - Arm CLOSED | EXPERIMENTAL | EGFR |
| Group 6 - Arm CLOSED | EXPERIMENTAL | high mutation burden, POLE, POLD1 |
| Group 7 - Arm CLOSED | EXPERIMENTAL | BRCA1, BRCA2, mutations in HRD |
| Group 8 - Arm CLOSED | EXPERIMENTAL | CDKN2A, CDK4, CCND1, SMARCA4 |
| Group 9 Arm CLOSED | EXPERIMENTAL | CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL |
| Group 10 Arm CLOSED | EXPERIMENTAL | AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2 |
| Group 11 - Arm CLOSED | EXPERIMENTAL | ERBB2 |
| Group 12 - Arm CLOSED | EXPERIMENTAL | BRAFV600 |
| Group 13 - Arm CLOSED | EXPERIMENTAL | PTCH1, SMO |
| Group 14 | EXPERIMENTAL | ERBB2 |
| Name | Type | Description |
|---|---|---|
| Olaparib | DRUG | 300mg taken twice daily |
| Dasatinib | DRUG | 100mg administered orally once daily |
| Nivolumab plus Ipilimumab | DRUG | * Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks. |
| Axitinib | DRUG | 5mg orally twice daily |
| Bosutinib | DRUG | 500mg orally once daily |
| Crizotinib | DRUG | 250mg orally twice daily |
| Palbociclib | DRUG | 125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days |
| Sunitinib | DRUG | 50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off |
| Temsirolimus | DRUG | 25mg infused over a 30-60 minute period once a week |
| Erlotinib | DRUG | 150mg orally, once daily |
| Trastuzumab plus Pertuzumab | DRUG | Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes. |
| Vemurafenib plus Cobimetinib | DRUG | Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest |
| Vismodegib | DRUG | 150mg taken orally, once daily |
| Tucatinib | DRUG | 300mg taken orally, twice daily |
Inclusion Criteria: (screening step - non-drug specific) * Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment...